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Available online 19 March 2016Sumoylation regulates transcription factor transactivation, protein-protein interactions, and appropriate subcel-
lular localization of certain proteins. Previous studies have shown that sumoylation of amyloid precursor protein
(APP) is associated with decreased levels of amyloid beta (Aβ) proteins, suggesting that sumoylation may play a
role in the pathogenesis of Alzheimer's disease (AD).We investigated the association between polymorphisms of
the SUMO genes and the risk of AD. Our study subjects consisted of 144 AD patients and 335 healthy controls
without dementia. We focused on tagged single nucleotide polymorphisms (tagSNPs) of the SUMO1 and
SUMO2 genes. The tagSNPswere ampliﬁed by PCR and sequenced.We used binary logistic regression to calculate
odds ratios (ORs) with 95% conﬁdence intervals (CIs) for the associations between SUMO gene polymorphisms
and the risk of AD. We found that rs12472035 polymorphism of SUMO1was signiﬁcantly associated with an in-
creased risk of AD inmale group (the CT genotype of rs12472035: adjusted OR=8.737, 95% CI=2.041–37.41, p-
value=0.003). In addition, two polymorphisms of SUMO2were signiﬁcantly associatedwith an increased risk of
AD in female group (the GA genotype of rs35271045: adjusted OR = 2.879, 95% CI = 1.399–5.924, p-value =
0.004; and the TC genotype of rs9913676: adjusted OR = 2.460, 95% CI = 1.197–5.057, p-value = 0.014). Fur-
thermore, three combinations were associated with an increased risk of AD. Our data suggest that three individ-
ual polymorphisms and three combinations may be potential risk factors for AD in Korean population.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Dementia is a general term for a decline in memory, cognitive skills,
and other mental processes, and is caused by damage to the nerve cells
of the brain; the neurons no longer function normally [1]. Worldwide,
35.6 million persons were estimated to have dementia in 2010, and
that number is projected to increase to 65.7 million by 2030 and 115.4
million by 2050. Approximately 7.7 million new cases of dementia are
diagnosed annually worldwide [2]. The various types of dementiaerval; SNP, single nucleotide
AD, Alzheimer's disease; FTLD,
ase; DLB, dementia with Lewy
yloid precursor protein; ER,
SENP, sentrin-speciﬁc proteases.
ankook Unversity Hospital, 201
16, South Korea.
. This is an open access article underexhibit distinct symptomatic patterns and brain abnormalities, and in-
clude Alzheimer's disease (AD), vascular dementia, frontotemporal
lobar degeneration (FTLD), dementia with Lewy body disease (DLB),
mixed dementia, dementia of Parkinson's disease (PD), and
Creutzfeldt-Jakob disease. Of these, AD is themost common form of de-
mentia, andwas ﬁrst identiﬁed over 100 years ago. However, the symp-
toms and causes of, and risk factors for, AD, have been clariﬁed only over
the last 30 years [1]. AD has two histopathological hallmarks. These are
extracellular aggregations of neuritic plaque, and neuroﬁbrillary tangles
(NFTs) in certain brain regions. TheNFTs are intracellular accumulations
of hyperphosphorylated tau protein [3]. The extracellular neuritic
plaques are insoluble deposits of variously sized amyloid beta (Aβ) pep-
tides derived fromamyloid precursor protein (APP). Secretases generate
Aβ in the endoplasmic reticulum (ER) and Golgi/trans-Golgi Network
(TGN). The ﬁrst step in Aβ peptide generation is cleavage of APP by β-
secretase, generating the β-carboxyterminal fragment termed βCTF.
This is further cleaved by γ-secretase, generating Aβ peptides [4,5].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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plays a major role in the regulation of normal protein functions.
Sumoylation regulates transcription factor transactivation, protein-
protein interactions, and subcellular localization of certain proteins
[6]. Sumoylation has three distinct steps, of which the ﬁrst is formation
of the mature small ubiquitin-related modiﬁer (SUMO) proteins from
nascent SUMO proteins via the action of SUMO-speciﬁc isopeptidases
(sentrin-speciﬁc proteases; SENPs). After proteolytic cleavage, the ma-
ture SUMO proteins are activated by the SUMO-speciﬁc E1-activating
enzyme (a heterodimer of AOS1 and UBA2). Next, the SUMO proteins
are transferred from the E1-activating enzyme to the E2-conjugating
enzyme UBC9. Finally, the SUMO proteins are covalently attached to ly-
sine residues of their target substrates by E3 ligase. Ultimately, the
SUMO proteins are removed from their target proteins by SENPs, to be-
come attached to other proteins as another sumoylation cycle com-
mences [7]. The human genome encodes four distinct SUMO proteins
(SUMO1, 2, 3, and 4) [8].
Previous studies found that sumoylation inﬂuenced the pathogenesis
of AD. Sumoylation of APP with either SUMO1 or SUMO2was associated
with reduced levels of Aβ species, whereas SUMO conjugation-deﬁcient
mutations replacing lysine residues (K587R, K595R) were associated
with higher levels of Aβ aggregates [9]. Furthermore, enhancement of
sumoylation via overexpression of the SUMO-speciﬁc E2-conjugating en-
zyme was associated with decreased levels of the Aβ aggregate [10].
Other studies have shown that overexpression of SUMO3 protein greatly
reduced Aβ levels in the HEK293 cell line [11]. In addition, down-
regulation of another SUMO-related enzyme, SENP3, was signiﬁcantly
associated with AD [12]. A polymorphism (rs761059) of the gene
encoding the SUMO-conjugating enzymeUbc9was signiﬁcantly associ-
ated with an increased risk of late-onset AD [13]. In addition, previous
data suggested that SUMO proteins are closely associated with the
risk of AD. So we hypothesized that polymorphisms in the SUMO1 and
SUMO2 genes might be associated with such risk, and investigated the
associations between such polymorphisms and the risk of AD in Korean
patients. To the best of our knowledge, this is the ﬁrst genetic study to
suggest a relationship between SUMO gene polymorphisms and the
risk of AD.
2. Materials and methods
2.1. Subjects
The study subjects consisted of 144 AD patients and 335 healthy
controlswithout dementia. Themean age of the AD group (119 females,
25males)was 79.82± 7.02 years and that of the controls (166 females,
169 males) 68.94 ± 6.10 years. The average educational level of the AD
group (2.92 ± 3.59 years) was lower than that of the control group
(8.29 ± 5.26 years). We deﬁne education level by years of education.
The frequencies of 10 SUMO genes polymorphisms in both groups are
summarized in Table 1.We recruited AD patients froma dementia clinic
of Dankook University Hospital. The cognitively normal control partici-
pantswere community-dwelling elderswhohad participated in the Ko-
rean Longitudinal Study on Cognitive Aging and Dementia (KLOSCAD)
and the Nationwide Dementia Screening and Registration Program
(NDSRP) [14]. All subjects underwent standardized clinical interviews
and neurological and physical examinations, administered by geriatric
psychiatrists with advanced training in neuropsychiatry and dementia
research. We used the Korean version of the protocol of the clinical as-
sessment battery established by the Consortium to Establish a Registry
for Alzheimer's Disease (CERAD-K) to diagnose dementia [15]. Demen-
tia was diagnosed using the criteria of the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition (DSM-IV), and probable or
possible AD was diagnosed using the criteria of the National Institute
of Neurological and Communicative Disorders and Stroke and the
Alzheimer's Disease and Related Disorders Association (NINCDS-
ADRDA) [16]. All participants were fully informed about the aims ofthe study and each participant, or his/her legal guardian, gave written
informed consent.
2.2. Assessment of neuropsychological functions
Global cognitive function was evaluated via Mini-Mental Status Ex-
amination (MMSE) [15,17]. To assess memory, the word list memory
test (WLMT), the word list recall test (WLRT), and the word list recog-
nition test (WLRcT) of the Korean version of the CERAD Neuropsycho-
logical Assessment Battery (CERAD-K-N) were administered. Language
function was evaluated using the verbal ﬂuency test (VFT). The 15-
item modiﬁed Boston Naming Test (mBNT) from the CERAD-K-N was
also employed [15,17]. Visuospatial function was evaluated using the
constructional praxis test (CPT) of the CERAD-K-N. Frontal function
was evaluated using the trail making test A and B of the CERAD-K-N
[15,17].
2.3. Genotyping analysis
First, we selected seven tagSNPs of the SUMO1 gene and two of the
SUMO2 gene based on linkage disequilibrium (LD) information and
minor allele frequencies (MAFs; cutoff 0.05) in the International
HapMap project database (Han Chinese subjects in Beijing, China; Chi-
nese and Japanese subjects in Tokyo, Japan) (Fig. 1). In addition, we in-
cluded a single intron polymorphism (+16446 CNG, lying between
exon 1 and exon 2 of the SUMO1 gene; the position is numbered from
the translation starting site). We thus genotyped 10 SNPs in total
(SUMO1: rs6761234, rs6709162, rs7599810, rs12472035, +16446
CNG, rs10185956, rs3769817 and rs12693965; SUMO2: rs35271045
and rs9913676) in 144 AD patients and 335 unrelated controls, using
PCR/sequencing. The primers used for genotyping were manually de-
signed, and were: rs6761234 forward, 5′-CTTACTCGGGATTGGTTCAT
CC-3′ and reverse, 5′-ACTCCTGATTAAGTGCAAATCCC-3′; rs6709162
forward, 5′-CAAAGTGCTCGTACAGAACCC-3′ and reverse, 5′-CTCACCTG
ACAACTAGCTGTTC-3′; rs7599810 forward, 5′-GGCCAGTTATGTTGTTGC
AG-3′ and reverse, 5′-ACGTCAGTGTGAAAGTGTCC-3′; rs12472035 and
+16446 CNG forward, 5′-TGTGCTGAGTAGCCGCTATAG-3′ and reverse,
5′-CTGACTATTACAGCAGCAGGC-3′; rs10185956 forward, 5′-GGAATT
GCTGGGTCTAGTATGC-3′ and reverse, 5′-TCAGGAAAGAGCAAGTTGAA
ACC-3′; rs3769817 forward, 5′-CCTTCAGTGACACTTCACTTGG-3′ and re-
verse, 5′-GGACGAACCTGTCTTTGACAG-3′; rs12693965 forward, 5′-
GGTGATGGTAACATTAATGGCTGG-3′ and reverse, 5′-CCCACATGCTGT
GCAATTTTAATTG-3′; rs35271045 forward, 5′-CTGTGCCCAGCAAGATAC
CAT-3′ and reverse, 5′-GACTGGTCTTCCAGCCTTGG-3′; and rs9913676
forward, 5′-GAGACCTGGAGTCTCGCACT-3′ and reverse, 5′-ATCTCGCT
GCACTGCTTAGC-3′. All PCR reactionswere performed on a C1000 Ther-
mal Cycler (Bio-Rad, Hercules, CA, USA) in a total volume of 25 μL con-
taining 2.5 mM MgCl2, 2.5 mM of each dNTP, 100 μM of each primer,
50 ng template DNA, and 1 unit of TaqDNA polymerase. The PCR proto-
col was as follows: initial denaturation at 94 °C for 5 min; 33 cycles of
94 °C for 30 s, 60 °C for 30 s, and 72 °C for 45 s; and a ﬁnal extension
at 72 °C for 3 min. DNA sequencing followed. PCR product directly se-
quenced using BigDye® Terminator v3.1 cycle sequencing kit on an
ABI 3730XL DNA sequencer (Applied Biosystems, Foster City, CA, USA).
2.4. Statistical analysis
All statistical analyses were performed using SPSS version 23.0
software (SPSS Inc., Chicago, IL, USA). The chi-squared test was
used to explore whether genotype distributions in the controls
were in Hardy-Weinberg Equilibrium (HWE). Odd ratio (OR) and
95% conﬁdence interval (95% CI) were calculated to estimate the
associations between different genotypes in AD patients and
healthy controls. Genotype analysis and combination analysis using binary
logistic regression adjusted for age, gender and education levels. The
LD between the nine tagSNPs was calculated by running pairwise
Table 1
Genotype analysis of SUMO genes ten polymorphisms in AD patients and controls.
SUMO1 rs6761234 (CNT), +830 Cases (n = 136) Controls (n = 333) Adjusted OR (95% CI)a p-Value HWE in control (p)
n % n %
Male CC 5 20.0 24 14.2 1
CT 15 60.0 74 43.8 2.521 (0.453–14.02) 0.291
TT 5 20.0 71 42.0 0.331 (0.048–2.275) 0.261 0.509
Total 25 169
Female CC 15 13.5 28 17.1 1
CT 54 48.6 76 46.3 1.541 (0.593–4.000) 0.375
TT 42 37.8 60 36.6 1.461 (0.544–3.924) 0.452 0.640
Total 111 164
SUMO1 rs6709162 (GNA), +4616 Cases (n = 142) Controls (n = 333) Adjusted OR (95% CI)a p-Value HWE in control (p)
n % n %
Male GG 11 44.0 88 52.1 1
GA 13 52.0 62 36.7 2.451 (0.702–8.557) 0.16
AA 1 4.0 19 11.2 0.127 (0.011–1.502) 0.101 0.120
Total 25 169
Female GG 53 45.3 70 42.7 1
GA 54 46.2 74 45.1 1.056 (0.548–2.037) 0.871
AA 10 8.5 20 12.2 0.542 (0.181–1.626) 0.275 0.948
Total 117 164
SUMO1 rs7599810 (CNT), +13907 Cases (n = 143) Controls (n = 334) Adjusted OR (95% CI)a p-Value HWE in control (p)
n % n %
Male CC 4 16.0 24 14.2 1
CT 16 64.0 71 42.0 4.144 (0.694–24.74) 0.119
TT 5 20.0 74 43.8 0.480 (0.070–3.272) 0.453 0.303
Total 25 169
Female CC 18 15.3 27 16.4 1
CT 55 46.6 77 46.7 1.362 (0.558–3.323) 0.497
TT 45 38.1 61 37.0 1.243 (0.496–3.116) 0.642 0.745
Total 118 165
SUMO1 +16446 CNG Cases (n = 140) Controls (n = 333) Adjusted OR (95% CI)a p-Value HWE in control (p)
n % n %
Male CC 4 16.0 25 14.8 1
CG 17 68.0 71 42.0 2.092 (0.370–11.82) 0.404
GG 4 16.0 73 43.2 0.331 (0.470–2.335) 0.268 0.263
Total 25 169
Female CC 19 16.5 26 15.9 1
CG 52 45.2 77 47.0 1.374 (0.559–3.376) 0.489
GG 44 38.3 61 37.2 1.229 (0.489–3.089) 0.661 0.836
Total 115 164
SUMO1 rs12472035 (CNT), +16482 Cases (n = 140) Controls (n = 333) Adjusted OR (95% CI)a p-Value HWE in control (p)
n (%) n (%)
Male CC 18 (72.0) 149 (88.2) 1
CT 7 (28.0) 20 (11.8) 8.737 (2.041–37.41) 0.003
TT 0 (0.0) 0 (0.0) 0.414
Total 25 169
Female CC 99 (86.1) 148 (90.2) 1
CT 16 (13.9) 16 (9.8) 1.901 (0.718–5.029) 0.196
TT 0 (0.0) 0 (0.0) 0.511
Total 115 164
SUMO1 rs10185956 (ANG), +20933 Cases (n = 142) Controls (n = 332) Adjusted OR (95% CI)a p-Value HWE in control (p)
n (%) n (%)
Male AA 11 (44.0) 86 (51.5) 1
AG 12 (48.0) 64 (38.3) 1.522 (0.456–5.080) 0.495
GG 2 (8.0) 17 (10.2) 0.484 (0.061–3.847) 0.493 0.328
Total 25 167
Female AA 52 (44.4) 70 (42.4) 1
AG 55 (47.0) 74 (44.8) 1.137 (0.590–2.190) 0.702
GG 10 (8.5) 21 (12.7) 0.551 (0.183–1.658) 0.289 0.834
Total 117 165
SUMO1 rs3769817 (ANG), +23888 Cases (n = 142) Controls (n = 332) Adjusted OR (95% CI)a p-Value HWE in control (p)
n (%) n (%)
Male AA 0 (0.0) 0 (0.0) NAb
AG 7 (28.0) 22 (13.1)
GG 18 (72.0) 146 (86.9) 0.364
Total 25 168
Female AA 0 (0.0) 0 (0.0) NA
AG 15 (12.8) 15 (9.1)
GG 102 (87.2) 149 (90.9) 0.539
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Table 1 (continued)
SUMO1 rs6761234 (CNT), +830 Cases (n = 136) Controls (n = 333) Adjusted OR (95% CI)a p-Value HWE in control (p)
n % n %
Total 117 164
SUMO1 rs12693965 (ANG), +28284 Cases (n = 143) Controls (n = 333) Adjusted OR (95% CI)a p-Value HWE in control (p)
n (%) n (%)
Male AA 0 (0.0) 0 (0.0) NA
AG 7 (28.0) 21 (12.5)
GG 18 (72.0) 147 (87.5) 0.388
Total 25 168
Female AA 0 (0.0) 0 (0.0) NA
AG 15 (12.7) 16 (9.7)
GG 103 (87.3) 149 (90.3) 0.513
Total 118 165
NA: not applicable.
Bold values means statistically signiﬁcant (p b 0.05).
a Logistic regression adjusted for age and levels of education.
b Not applicable (NA) because of absence of the subjects with homozygote wild type.
125M.-J. Mun et al. / Journal of the Neurological Sciences 364 (2016) 122–127comparisons with the aid of Haploview software (Broad Institute,
Cambridge, MA, USA). A two-tailed p-value b 0.05 was considered
to indicate statistical signiﬁcance.
3. Results
The genotype distributions in both AD patients and controls did not
deviate fromHWE (p N 0.05). The genotyping failure ratewas 1.41%.We
found no signiﬁcant differences in genotype frequencies between the
AD and control groups when the statistical test was used to analyze
data on the seven SUMO1 polymorphisms.Wedid not identify polymor-
phisms of the major alleles rs3769817 and rs12693965. However, the
CT genotype of the rs12472035 polymorphismwas signiﬁcantly associ-
ated with an increased risk of AD in male group (adjusted OR: 8.737,
95% CI: 2.041–37.41), p-value: 0.003). We found that two SUMO2 poly-
morphisms were signiﬁcantly associated with the risk of AD in female
group (the GA genotype of rs35271045: adjusted OR = 2.879, 95%
CI = 1.399–5.924, p-value = 0.004; and the TC genotype of
rs9913676: adjusted OR = 2.460, 95% CI = 1.197–5.057, p-value =
0.014). We also investigated the associations between combinations of
polymorphisms and the risk of AD. We constructed eight combinations
of SUMO gene polymorphisms (combination 1–8: rs6761234-
rs6709162-rs12472035, rs6761234-rs7599810-+16446 CNG,
rs6761234-rs7599810-rs12472035, rs6761234-+16446 CNG-
rs12472035, rs6761234-rs12472035-rs10185956, rs7599810-+16446
CNG-rs12472035, rs6761234-rs7599810-+16446 CNG-rs12472035
and rs35271045-rs99113676) for both AD patients and controls. Only
eight combinations of SUMO polymorphisms had reference allele in
both AD cases and controls. Of these, ﬁve combinations (1, 2, 5, 7 and
8)were not signiﬁcantlywith the risk of AD (data not shown). However,
combination 3, 4 and 6 were signiﬁcantly associated with an increased
risk of AD (T-T-T type of combination 3: adjusted OR = 5.690, 95%
CI = 1.320–24.52, p-value = 0.020; T-G-T type of combination 4: ad-
justed OR = 5.935, 95% CI = 1.388–25.38, p-value = 0.016; T-G-T
type of combination 6: adjusted OR = 5.299, 95% CI = 1.244–22.58, p-
value = 0.024). The data are summarized in Table 2.
4. Discussion
Genetic variants are common genome-wide and often indicate
connections between certain genes and disease. Of the several types
of genetic variants, polymorphisms are apparent in at least 1% of the
population. Polymorphisms in the regulatory regions of genes may
affect the level of gene expression and protein function. For example,
changes in APP sumoylation sites (K587R and K595R) near the
β-secretase target region affect the levels of Aβ aggregates [9].In recent decades, many studies have identiﬁed genetic risk factors
for AD. Polymorphisms in amyloid precursor protein (APP), presenilin-
1 (PSEN1) and presenilin-2 (PSEN2) are associated with susceptibility
to early-onset familial AD (EOFAD) [18]. In addition, the ε4 variant of
apolipoprotein E (ApoE) is closely associated with an increased risk of
late-onset Alzheimer's disease (LOAD) [19]. Verghese et al. suggested
that ApoE variants were signiﬁcantly associated not only with AD but
also with several other neurological disorders [20]. Recently, large
genome-wide association studies (GWAS) have found that variants in
20 genes (9 known genes: CR1, BIN1, CD2AP, EPHA1, CLU1, MS4A6A,
PICALM, ABCA7 and CD33; 11 new genes: HLA-DRB5-HLA-DRB1, PTK2B,
SORL1, SLC24A4-RIN3, DSG2, INPP5D, MEF2C, NME8, ZCWPW1, CELF1,
FERMT2 and CASS4) were signiﬁcantly associated with the risk of AD
[21]. Also, several studies have used next-generation sequencing
(NGS) to discover new genetic variants in AD patients. In fourteen
large familieswith LOAD,whole-exome sequencing (WES) data indicat-
ed that variants in phospholipase 3 (PLD3) were signiﬁcantly associated
with AD. Similarly, replication analysis suggested that PLD3 genetic var-
iants were associated with a much-increased risk of AD in 11,000 sub-
jects of European descent. In addition, it was found that PLD3
overexpression was signiﬁcantly associated with reduced levels of
both intracellular APP and extracellular Aβ, whereas PLD3 knockdown
increased Aβ levels [22]. Another WES study on AD found that two
rare variants of A-kinase anchor protein 9 (AKAP9) were signiﬁcantly
associated with AD. Replication analysis conﬁrmed that these two rare
variants were associated with an increased risk of AD in 2906 subjects
[23]. Thus, many potential biomarkers of AD have been discovered
with the aid of various techniques. However, the associations between
these potential biomarkers and the risk of AD remain unclear.
The SUMO1 gene is located on chromosome 2, and is 32,429 bp in
length (exons 1 to 5, including the intronic regions). The International
HapMap database identiﬁes nine tagSNPs in the CHB + JPT database
(rs10167674, rs6761234, rs13000658, rs7599810, rs12472035,
rs10185956, rs3769817, and rs12393965). However, the MAFs of
rs10167674 and rs13000658 are 0.0 and 0.006, respectively. The
SUMO2 gene is located on chromosome 17, and is 17,398 bp in length
(exons 1 to 4, including the intronic regions). The International HapMap
database identiﬁes seven tagSNPs in the CHB + JPT database
(rs9913676, rs2035252, rs899324, rs899323, rs35271045, rs1471453,
and rs7213926). Of these, the MAFs of ﬁve (rs2035252, rs899324,
rs899323, rs1471453, and rs7213926) are 0.0. In this case-control
study, we explored the associations between 10 SUMO gene polymor-
phisms and the risk of AD in Korean subjects. We found that one poly-
morphism (rs12472035) of the SUMO1 gene, and two polymorphisms
(rs35271045 and rs9913676) of the SUMO2 gene, were signiﬁcantly as-
sociated with an increased risk of AD. In addition, combination analysis
Fig. 1. Schematic representation of SUMO genes. (a) The exon and intron structure of SUMO1 gene and the position of eight polymorphisms. (b) The exon and intron structure of SUMO2
gene and the position of two polymorphisms. (c) Linkage disequilibrium (LD) map pattern of SUMO1 gene nine tagSNPs. (d) LD map pattern of SUMO 2 gene seven tagSNPs. Dark gray
color indicates the strong LD. Bold highlight indicates the LD Block. The numbers in each box represent the D′ value. The LD plot generated by Haploview software and HapMap database
(www.hapmap.org).
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highly increased risk of AD.
Our study had two limitations. First, we had relatively few cases and
controls. This reduces the statistical power of the observed associations
between ten SUMO genes polymorphisms and the risk of AD. Second,
we did not consider gene-gene interactions; or gene-environmentalinteractions such as smoking status, alcohol use status, or disease
state. These may affect associations between SUMO gene polymor-
phisms and the risk of AD.
In conclusions, our data suggest that three SUMO polymorphisms,
and combinations of polymorphisms, may be AD potential risk factors.
Further work with large numbers of subjects is needed to conﬁrm the
Table 2
Combination analysis of SUMO1 gene polymorphisms in AD patients and controls.
n (%) n (%) Adjusted OR (95%
CI)a
p-Value
Combination 3
rs6761234 (CNT)
rs7599810 (CNT)
rs12472035
(CNT)
C-C-C 11 (8.3) 36 (10.8) 1.000
T-C-C 1 (0.8) 3 (0.9) 1.133
(0.098–13.13)
0.921
C-T-C 1 (0.8) 3 (0.9) 1.396
(0.054–35.98)
0.840
C-C-T 8 (6.0) 11 (3.3) 3.006
(0.729–12.40)
0.128
T-T-C 98 (73.7) 254
(76.5)
1.829
(0.691–4.840)
0.224
T-C-T 0 0
C-T-T 0 1 (0.3)
T-T-T 14 (10.5) 24 (7.2) 5.690
(1.320–24.52)
0.020
Total 133 332
Combination 4
rs6761234 (CNT)
+16446 (CNG)
rs12472035
(CNT)
C-C-C 11 (8.3) 38 (11.4) 1.000
T-C-C 2 (1.5) 4 (1.2) 2.252
(0.191–26.48)
0.519
C-G-C 1 (0.8) 1 (0.3) 1.810
(0.051–64.68)
0.745
C-C-T 8 (6.0) 8 (2.4) 4.043
(0.904–18.08)
0.068
T-G-C 97 (72.9) 253
(76.2)
1.797
(0.676–4.774)
0.240
T-C-T 0 1 (0.3)
C-G-T 0 4 (1.2)
T-G-T 14 (10.5) 23 (6.9) 5.935
(1.388–25.38)
0.016
Total 133 332
Combination 6
rs7599810 (CNT)
+16446 (CNG)
rs12472035
(CNT)
C-C-C 12 (8.6) 35 (10.5)
T-C-C 2 (1.4) 7 (2.1) 1.460
(0.150–14.21)
0.744
C-G-C 1 (0.7) 4 (1.2) 0.804
(0.074–8.801)
0.858
C-C-T 9 (6.5) 7 (2.1) 4.137
(0.932–18.36)
0.062
T-G-C 101
(72.7)
251
(75.6)
1.688
(0.656–4.344)
0.277
T-C-T 0 2 (0.6)
C-G-T 0 4 (1.2)
T-G-T 14 (10.1) 22 (6.6) 5.299
(1.244–22.58)
0.024
Total 139 332
Bold values means statistically signiﬁcant (p b 0.05).
a Logistic regression adjusted for age, gender and levels of education.
127M.-J. Mun et al. / Journal of the Neurological Sciences 364 (2016) 122–127relationship between SUMO gene polymorphisms and the risk of AD;
environmental factors should also be examined. Also, it is necessary to
assess possible associations between polymorphisms in SUMO-related
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